Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer

• Main Authors: Hisashi Hirano, Hisamitsu Ide, Yan Lu, Yasuyuki Inoue, Hiroshi Okada, Shigeo Horie
• Format: Article
• Language: English
• Published: SAGE Publishing 2020-04-01
• Series: American Journal of Men's Health
• Online Access: https://doi.org/10.1177/1557988320918788

Metabolic syndrome is reported to play a role in the genesis and development not only of angina, arteriosclerosis, diabetes, and osteoporosis but also of prostate cancer. Hypercholesterolemia is a strong risk factor in prostate cancer development. The current study was conducted to analyze whether pretreatment serum levels of cholesterol correlate with prostate cancer metastasis. Three hundred fifty-one subjects who received a histopathological diagnosis of prostate cancer were evaluated by clinical factors such as age, body mass index (BMI), disease stage, Gleason score, prostate-specific antigen (PSA), total cholesterol, Luteinizing hormone (LH), testosterone, and free testosterone. A multivariate analysis was performed on these factors, and a statistically significant difference was identified in total cholesterol level ( p =.01) and PSA ( p < .001). The total cholesterol level was higher in cases of metastatic prostate cancer compared to nonmetastatic prostate cancer in this study and therefore may be a predictive factor for poor prognosis.